Home / Market News / $AMGN

$AMGN news and market catalysts

The 50 most recent market catalysts affecting $AMGN, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.

50 catalysts 7 high impact 39 bullish 7 bearish Biotechnology
Nov 16, 2026 Corporate Catalyst Bullish Impact 55
Barclays Adjusts Price Target on Amgen to $430 From $400
Barclays, a major financial institution, has raised its price target for Amgen (AMGN) shares from $400 to $430. This action signals a more optimistic view from the analyst firm reg…
Nov 12, 2026 Corporate Catalyst Bullish Impact 65
Argus Research Adjusts Amgen Price Target to $515 From $460
Argus Research adjusted its price target for Amgen Inc. upwards to $515 from $460, reflecting an improved outlook for the biotechnology company. This positive revision is attribute…
Nov 11, 2026 Corporate Catalyst Bullish Impact 85
Amgen Announces Positive Phase 3 Results for Dazodalibep in Sjögren's Disease
Amgen announced that its Phase 3 OASIZ-301 study for dazodalibep in Sjögren's disease successfully met its primary endpoints, demonstrating clinically meaningful improvements. This…
Nov 11, 2026 Corporate Catalyst Bullish Impact 55
Daiwa Securities Adjusts Price Target on Amgen
Daiwa Securities adjusted its price target for Amgen Inc. upwards from $430 to $490. This action reflects a more favorable view from the analyst firm regarding Amgen's future valua…
Nov 5, 2026 Corporate Catalyst Bullish Impact 55
Guggenheim Adjusts Price Target on Amgen to $435
Guggenheim, a financial firm, has updated its outlook on Amgen, raising its price target to $435. This is a positive signal in isolation, as a higher price target generally indicat…
Nov 5, 2026 Corporate Catalyst Bullish Impact 75
Amgen Announces Real-World Study Results for Repatha
Amgen disclosed positive real-world study results for Repatha, showing it significantly reduces heart disease risk compared to ezetimibe. This is a crucial development as real-worl…
Nov 5, 2026 Corporate Catalyst Bullish Impact 55
Amgen Price Target Raised by Analyst
An analyst has raised their price target for Amgen Inc. to $400 from $345, reflecting an updated and more favorable valuation. This matters because analyst price target revisions c…
Nov 4, 2026 Corporate Catalyst Bullish Impact 75
Amgen Announces Positive Phase 3 Clinical Results and FDA Labeling Update
Amgen reported positive Phase 3 results for dazodalibep in Sjögren's disease, meeting its primary endpoint, which is a significant step towards potential market approval and a new …
Nov 3, 2026 Corporate Catalyst Bullish Impact 85
Amgen Raises Full-Year Outlook Following Strong Third-Quarter Results
Amgen announced better-than-expected third-quarter 2026 financial results, with revenue and adjusted EPS surpassing consensus estimates. This outperformance was attributed to robus…
Oct 28, 2026 Corporate Catalyst Bearish Impact 55
FDA Reviews Amgen's Video for VECTIBIX Injection
The FDA has determined that Amgen's promotional video for VECTIBIX, a cancer treatment, was false or misleading. This matters because it signals a regulatory breach under the Feder…
Oct 27, 2026 Corporate Catalyst Neutral Impact 65
Amgen Announces Upcoming Data Presentations for ACR Convergence 2026
Amgen's 8-K filing announces upcoming data presentations at a major rheumatology conference, with the most significant disclosure being positive Phase 3 results for dazodalibep in …
Oct 27, 2026 Corporate Catalyst Bullish Impact 55
NORD and Amgen Launch Learning Collaborative for Rare Disease Diagnosis
Amgen is partnering with NORD to launch a 'Learning Collaborative' focused on improving the diagnosis and care of rare autoimmune conditions. This 14-month pilot program, involving…
Oct 23, 2026 Corporate Catalyst Bullish Impact 55
Oppenheimer Adjusts Amgen Price Target to $480 From $450
Investment firm Oppenheimer updated its outlook on Amgen Inc., raising its price target from $450 to $480 and maintaining an Outperform rating. This adjustment signals Oppenheimer'…
Oct 20, 2026 Corporate Catalyst Bullish Impact 85
Amgen shares are trading higher after the company and AstraZeneca reported that TEZSPIRE improved histologic remission and dysphagia in a Phase 3 trial for eosinophilic esophagitis.
The positive Phase 3 trial results for TEZSPIRE in eosinophilic esophagitis represent a significant clinical and commercial win for Amgen and AstraZeneca. Eosinophilic esophagitis …
Oct 20, 2026 Corporate Catalyst Bullish Impact 75
Amgen, AstraZeneca Announces Data From Phase 3 CROSSING Study Demonstrated TEZSPIRE Showed Histologic Remission For 64.8% For 210 Mg Dose At Week 24; TEZSPIRE Also Reduced Frequency, Severity Of Dysphagia Symptoms 18.8 Points
Amgen and AstraZeneca announced full positive results from their Phase 3 CROSSING trial for TEZSPIRE in treating eosinophilic esophagitis (EoE). The trial showed TEZSPIRE achieved …
Oct 13, 2026 Corporate Catalyst Bearish Impact 55
Guggenheim Maintains Neutral on Amgen, Lowers Price Target to $378
Guggenheim analyst Vamil Divan maintained a 'Neutral' rating on Amgen but lowered the price target by $10, from $388 to $378. This action suggests a slightly diminished valuation o…
Oct 9, 2026 Corporate Catalyst Bullish Impact 55
UBS Maintains Buy on Amgen, Raises Price Target to $470
UBS analyst Michael Yee has maintained a 'Buy' rating for Amgen and raised the price target from $430 to $470. This action signals increased confidence from a prominent financial i…
Oct 8, 2026 Corporate Catalyst Bullish Impact 55
RBC Capital Maintains Outperform on Amgen, Raises Price Target to $430
RBC Capital analyst Luca Issi maintained an 'Outperform' rating on Amgen and raised the price target from $400 to $430. This action signals continued confidence in Amgen's future p…
Oct 7, 2026 Corporate Catalyst Bullish Impact 55
Truist Securities Maintains Hold on Amgen, Raises Price Target to $380
Truist Securities analyst Gregory Renza has maintained a 'Hold' rating on Amgen (AMGN) but raised the price target from $362 to $380. This action suggests that while the analyst se…
Sep 29, 2026 Corporate Catalyst Bullish Impact 55
Scotiabank Maintains Sector Outperform on Amgen, Raises Price Target to $500
Scotiabank analyst Louise Chen has maintained a 'Sector Outperform' rating on Amgen and raised the price target from $450 to $500. This action signals a strong vote of confidence i…
Sep 22, 2026 Corporate Catalyst Bullish Impact 75
Amgen Hits Primary Endpoint In Sjögren's Trial, But Approval Filing Awaits Another Trial Data
Amgen reported encouraging topline results for dazodalibep in its Phase 3 OASIZ 301 study for Sjögren's disease, a significant milestone given the historical difficulties in SjD dr…
Sep 22, 2026 Corporate Catalyst Bullish Impact 85
Amgen shares are trading higher after the company announced the Phase 3 OASIZ 301 study evaluating dazodalibep in adults with Sjögren's disease and moderate-to-severe systemic disease activity met its primary endpoint.
This headline represents a significant positive catalyst for Amgen. Successful Phase 3 clinical trials are crucial milestones in drug development, de-risking future revenue potenti…
Sep 22, 2026 Corporate Catalyst Bullish Impact 75
Amgen Announces Its Phase 3 OASIZ 301 Trial Of Dazodalibep To Treat Sjogren's Disease Meets Primary Endpoint, Shows Improvement In Systemic Disease Activity At Week 48
Amgen announced that its Phase 3 OASIZ 301 trial for dazodalibep, targeting Sjögren's disease, successfully met its primary endpoint. This is a significant development as it indica…
Sep 10, 2026 Corporate Catalyst Bearish Impact 65
HSBC Downgrades Amgen to Hold, Lowers Price Target to $425
HSBC analyst Morten Herholdt downgraded Amgen from a 'Buy' to a 'Hold' rating and lowered the price target from $445 to $425. This action signals a reduced confidence in Amgen's fu…
Sep 8, 2026 Corporate Catalyst Bearish Impact 75
What's Going On With Amgen Stock Tuesday?
Novartis's pelacarsen, an Lp(a)-lowering drug, failed its Phase 3 trial to reduce major cardiovascular events. This is significant because Amgen is developing olpasiran, another Lp…
Sep 8, 2026 Corporate Catalyst Bearish Impact 85
Amgen shares are trading lower amid sympathy with Novartis after that company's pelacarsen phase III trial failed to reach its primary endpoint, with investors assessing the impact on AMGN's olpasiran phase III study. Also, BMO Capital downgraded its rating on the stock from Outperform to Market Perform and maintained its $450 price target.
The headline presents a significant corporate catalyst for Amgen, driven by a negative read-across from a competitor's failed drug trial. The 'sympathy' selling indicates investor …
Sep 8, 2026 Corporate Catalyst Bearish Impact 55
BMO Capital Downgrades Amgen to Market Perform, Maintains Price Target to $450
BMO Capital's downgrade of Amgen from 'Outperform' to 'Market Perform' signals a shift in the analyst's confidence regarding the stock's future performance relative to the broader …
Aug 31, 2026 Corporate Catalyst Bullish Impact 75
Reported Earlier, Amgen Says Repatha Cut Death Risk By 20% In High-Risk Heart Patients
Amgen reported that its drug Repatha significantly reduced the risk of death by 20% in high-risk heart patients without a prior heart attack or stroke. This is a major positive dev…
Aug 27, 2026 Corporate Catalyst Bullish Impact 75
Amgen And AstraZeneca's TEZSPIRE Meets Both Co-Primary And All Key Secondary Endpoints In Phase 3 CROSSING Trial For Eosinophilic Esophagitis
Amgen and AstraZeneca reported that their co-developed drug, TEZSPIRE, successfully met both co-primary and all key secondary endpoints in the Phase 3 CROSSING trial for Eosinophil…
Aug 20, 2026 Corporate Catalyst Bullish Impact 55
Piper Sandler Maintains Overweight on Amgen, Raises Price Target to $457
Piper Sandler analyst David Amsellem has maintained an 'Overweight' rating on Amgen and raised the price target from $427 to $457. This action signals increased confidence from the…
Aug 19, 2026 Corporate Catalyst Bullish Impact 75
Amgen shares are trading higher after Argus Research raised its price target on the stock from $375 to $460.
The analyst upgrade from Argus Research, raising Amgen's price target by a substantial margin, acts as a strong positive catalyst for the stock. This indicates that the research fi…
Aug 19, 2026 Corporate Catalyst Bullish Impact 55
Argus Research Maintains Buy on Amgen, Raises Price Target to $460
Argus Research analyst Jasper Hellweg maintained a 'Buy' rating on Amgen and significantly raised the price target from $375 to $460. This upgrade reflects a more optimistic view o…
Aug 18, 2026 Corporate Catalyst Bullish Impact 55
Mizuho Maintains Neutral on Amgen, Raises Price Target to $352
Mizuho analyst Salim Syed has maintained a 'Neutral' rating on Amgen (AMGN) but significantly increased the price target from $303 to $352. This action indicates that while the ana…
Aug 14, 2026 Corporate Catalyst Bullish Impact 55
Barclays Maintains Equal-Weight on Amgen, Raises Price Target to $380
Barclays analyst Emily Field maintained an 'Equal-Weight' rating on Amgen but raised the price target from $360 to $380. This action signals a modest increase in the analyst's valu…
Aug 12, 2026 Corporate Catalyst Bullish Impact 55
Reported Earlier, Amgen To Open New Science And Innovation Center At Genome Valley In Hyderabad
Amgen is expanding its global Research and Development network by opening a new science and innovation center in Genome Valley, Hyderabad, India, slated for 2027. This move is sign…
Aug 7, 2026 Corporate Catalyst Neutral Impact 65
Chubb, Toast And A Health Care Stock On CNBC’s ‘Final Trades’
The filing details three companies that were recommended on CNBC's 'Final Trades' segment, primarily due to their recent strong earnings reports. Chubb and Toast both beat earnings…
Aug 6, 2026 Corporate Catalyst Neutral Impact 55
CNBC Halftime Report Final Trades: Amgen, Toast, Chubb
The headline signals that these three stocks were featured as 'final trades' on a popular financial news program, implying they were recommended for short-term action by panelists.…
Aug 6, 2026 Corporate Catalyst Bullish Impact 55
Bernstein Maintains Market Perform on Amgen, Raises Price Target to $345
Bernstein analyst Courtney Breen maintained a 'Market Perform' rating on Amgen but raised the price target from $335 to $345. This indicates that while the analyst sees some upside…
Aug 5, 2026 Corporate Catalyst Bullish Impact 55
UBS Maintains Buy on Amgen, Raises Price Target to $440
UBS analyst Michael Yee maintained a 'Buy' rating on Amgen and raised the price target from $420 to $440. This action signals an analyst's continued positive outlook on Amgen's fin…
Aug 5, 2026 Corporate Catalyst Bullish Impact 55
TD Cowen Maintains Buy on Amgen, Raises Price Target to $452
TD Cowen analyst Yaron Werber maintained a 'Buy' rating on Amgen and raised the price target from $420 to $452. This indicates a positive outlook from a prominent financial institu…
Aug 5, 2026 Corporate Catalyst Bullish Impact 55
Oppenheimer Maintains Outperform on Amgen, Raises Price Target to $450
Oppenheimer analyst Jay Olson maintained an 'Outperform' rating on Amgen and raised the price target from $400 to $450. This action signals increased confidence in Amgen's future p…
Aug 5, 2026 Corporate Catalyst Bullish Impact 55
Scotiabank Maintains Sector Outperform on Amgen, Raises Price Target to $450
Scotiabank analyst Louise Chen has maintained a 'Sector Outperform' rating on Amgen and raised the price target from $385 to $450. This action signals increased confidence from the…
Aug 5, 2026 Corporate Catalyst Bullish Impact 55
RBC Capital Maintains Outperform on Amgen, Raises Price Target to $400
RBC Capital's analyst Luca Issi has raised the price target for Amgen (AMGN) from $370 to $400 while maintaining an Outperform rating. This action signals increased confidence from…
Aug 5, 2026 Corporate Catalyst Bullish Impact 95
Amgen shares are trading higher after the company reported better-than-expected Q2 financial results, raised its FY26 adjusted EPS guidance with its midpoint above estimates and raised its FY26 sales guidance above estimates. Also, BMO Capital maintained its Outperform rating and raised its price target from $400 to $450.
This headline is a major positive catalyst for Amgen. Better-than-expected earnings and, more importantly, significantly raised long-term guidance (FY26 EPS and sales) signal stron…
Aug 5, 2026 Corporate Catalyst Bullish Impact 55
BMO Capital Maintains Outperform on Amgen, Raises Price Target to $450
BMO Capital analyst Evan David Seigerman has maintained an 'Outperform' rating on Amgen and raised the price target from $400 to $450. This action signals a strengthened conviction…
Aug 4, 2026 Corporate Catalyst Bullish Impact 65
Amgen Exec Says Spent $500M In Q2 On Capital Expenditures, Driven By Investments Across U.S. Manufacturing Sites; Continues To Expect Capital Expenditures Of About $2.6B In 2026 To Scale Manufacturing Capacity, Including For Maritide's Launch; Expect A Meaningful Sequential Increase In Operating Expenses In Q3
Amgen's disclosure of $500 million in Q2 capital expenditures and the reaffirmation of $2.6 billion in capex for 2026 signals significant investment in manufacturing infrastructure…
Aug 4, 2026 Corporate Catalyst Neutral Impact 65
Amgen Discontinuing Future Development Of AMG 513; To Continue Phase 1 Trial Of AMG 513 In Adults With Obesity
Amgen has decided to cease future development of AMG 513, an obesity drug candidate. This is significant because it removes a potential future revenue stream and growth driver from…
Aug 4, 2026 Corporate Catalyst Bullish Impact 92
Amgen Q2 Adj. EPS $6.29 Beats $5.62 Estimate, Sales $10.054B Beat $9.421B Estimate
Amgen's Q2 results show a substantial beat on both adjusted EPS and sales estimates, with earnings up 4.49% year-over-year and sales up 9.53%. This indicates strong underlying busi…
Jul 24, 2026 Corporate Catalyst Bearish Impact 65
Amgen Disagrees With FDA Proposal To Withdraw TAVNEOS From U.S. Market; Submitted Data And Analyses To FDA To Request Hearing On TAVNEOS
Amgen has publicly stated its disagreement with the FDA's proposal to withdraw TAVNEOS (avacopan) from the U.S. market. The company has submitted comprehensive data and analyses to…
Jul 13, 2026 Corporate Catalyst Bullish Impact 55
UBS Maintains Buy on Amgen, Raises Price Target to $420
UBS analyst Michael Yee has updated his outlook on Amgen, raising the price target from $400 to $420 while keeping a 'Buy' rating. This action indicates a continued positive sentim…
Join the waitlist for full signal validation →

Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.